Journal of Medicinal Chemistry · 2004 · 103 citations · 15 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryMolecular PharmacologyLigand BindingOncology PharmacologyStructure-activity Relationship AnalysisBackbone ProtonationBcr-abl InhibitorsBcr-abl1 Fusion GeneChronic Myeloid Leukemia TherapyGastric Ph AssessmentGastric Ph RegulationGastric Ph-mediated InteractionsMechanistic Hypotheses
The site-specific basicities of imatinib (Gleevec, a new signal transduction inhibitor drug of chronic myeloid leukemia) and two of its fragment compounds were quantitated in terms of protonation macroconstants, microconstants, and group constants by NMR-pH and pH-potentiometric titrations. Sequential protonation of imatinib follows the N(34), N(11), N(31), N(13) order, in which N(11) and N(31) show commensurable basicity, but negligible intramolecular interaction. Fragment compounds include two "halves" of imatinib, and their moiety-specific basicities confirm the NMR-based protonation sequence of the parent compound. NMR-pH profiles, macro- and/or microscopic protonation schemes, and species-specific distribution diagrams are presented. On the basis of these data, imatinib is shown to be predominantly neutral, monocationic, and tricationic at intestinal, blood, and gastric pH, respectively. The molecular hypotheses on imatinib binding to the Bcr-Abl oncogene fusion protein are interpreted at the site-specific level in view of the moiety basicities of imatinib.
15
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Thomas H. Schindler, William G. Bornmann, Patricia Pellicena et al. · Science · 2000 · 1.8K citations
H. M. N. H. Irving, Malcolm G. Miles, Leslie D. Pettit · Analytica Chimica Acta · 1967 · 1.3K citations